-
Amid Exec Departure, Teva's 2017 Outlook Now More Important Than Ever
Tuesday, December 6, 2016 - 12:34pm | 316Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced that Dipankar Bhattacharjee, the CEO of Teva generics Europe, has been appointed as the new head of global generics. Deutsche Bank’s Gregg Gilbert maintains a Buy rating on the company, with a price target of $54. Executive...
-
Teva Investors May Question If Exec Departure Reflects Deeper Malaise
Tuesday, December 6, 2016 - 10:22am | 344Read More...Bernstein said the departure of Siggi Olafsson is negative for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), as investors may fear the move is reflective of deeper malaise. ADRs of Teva were down 3.89 percent in Tuesday’s pre-market hours. Olafsson's Departure Teva announced that...
-
Key Exec Announcing His Retirement From Teva 'Creates More Uncertainties'
Tuesday, December 6, 2016 - 9:45am | 304Read More...After Monday's close, Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced Siggi Olafsson, head of global generics at the company, would be retiring at the end of Q1:17. BTIG’s Timothy Chiang maintains a Neutral rating on the company, while expressing surprise regarding the...
-
Barclays Is Boosting Teva's PT
Thursday, April 9, 2015 - 4:01pm | 253Read More...Barclays raised its price target on Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) Thursday to $80 and maintained an Overweight rating. The analyst note followed a meeting with Teva CEO Siggi Olafsson. Analyst Douglas D. Tsao believed believed TEVA had a lot of things go its way...
-
Does Teva Pharmaceutical's New Executive Hint At A Coming M&A Deal?
Tuesday, March 24, 2015 - 10:17am | 216Read More...In a report published Monday, Citigroup analyst Liav Abraham hypothesized that Teva Pharmaceutical Industries Ltd (NYSE: TEVA) recent hire of Timothy Wright as Head of Business Development suggests that a "material, potentially transformative transaction is not off the table." Abraham noted that...
